BDSI Wins Ruling In Bid to Block Alvogen’s Generic Belbuca (1)

(Updates with share activity beginning in first bullet.)

BioDelivery Sciences rose as much as 11% after it won a court ruling that upheld the validity of two of its patents on the painkiller Belbuca and will prevent Alvogen from selling a generic version of the drug for a decade.

• Trial judge in Delaware upheld the validity of claims in BDSI patent 8,147,866, which expires in 2027, and 9,901,539, which ends in 2032
• District Judge Colm Connolly said some claims of the ‘866 patent and of a third BDSI patent expiring in 2027, the 9,655,843 patent, are invalid
• NOTE: BDSI settled ...